Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen

Figures & data

Table 1 Patient baseline demographics

	Amlodipine/atorvastatin	Amlodipine + atorvastatin	Amlodipine + other statin	Other CCB + atorvastatin	Other CCB + other statin
Patients
(N = 4703)	n = 795	n = 735	n = 1163	n = 652	n = 1358
Ageb, mean (SD) years	61.4 (12.0)	62.8 (12.6)	63.1 (12.1)	62.1 (11.4)	64.4 (12.3)
Femaleb, %	42.5	55.6	47.8	57.5	55.3
Drugs at baselineb, mean (SD)	6.0 (5.0)	8.1 (5.0)	8.2 (5.1)	8.2 (5.1)	8.1 (5.3)
Business typeb, %
Commercial (MCO)	81.0	68.8	75.5	66.4	56.4
Medicaid	2.4	17.1	7.9	19.2	9.7
Medicare	0.9	1.9	3.3	2.0	18.3
Self-insured	15.7	10.5	12.0	10.0	10.7
Number of drug classes utilized(b,c)	6.6	7.4	7.6	7.6	7.5
Maintenance medication refilla, %	57.1	60.9	62.5	60.3	59.9
Statin (CCB new start)b, %	61.3	54.5	62.9	36.5	42.3
CCB (statin new start)b, %	38.6	45.4	37.0	63.4	57.6
Medication usage, %
ACE inhibitorb	36.6	46.5	43.4	41.2	42.4
Beta-blockerb	36.8	42.8	43.5	31.7	29.3
Diuretica	9.4	14.9	15.2	14.4	13.8
ARBb	29.3	19.4	24.0	17.3	13.5
Coronary vasodilatora	8.4	12.5	12.2	11.0	9.7
Digoxinb	1.5	2.9	4.1	5.6	5.8
Platelet aggregation inhibitorb	11.1	10.2	10.0	9.0	5.8
Antidiabetic agenta	25.5	30.2	32.4	31.4	28.6
Antidepressanta	17.2	20.5	19.3	22.3	22.3

a p < 0.05;

b p < 0.0001 tests for differences among all cohorts

c Number of drugs classes utilized based on First DataBank (First DataBank Inc. 2006) therapeutic categories.

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; MCO, managed care organization.

Figure 1 (A) Unadjusted mean PDC, and (B) percentage of patients achieving the primary adherence endpoint (PDC ≥ 80%) at 180 days’ follow-up.

*p < 0.0001 amlodipine/atorvastatin vs all other cohorts.

Abbreviations: CCB, calcium channel blocker; PDC, proportion of days covered.

Figure 2 Adjusted probability of achieving adherence (PDC ≥ 80%) at 180 days’ follow-up. Logistic regression model analysis adjusting for covariates including age, gender, business type, formulary type, baseline antihypertensive therapy, cardiovascular disease medications, antidiabetic medications, antidepressants, number of drugs, co-payments, and maintenance medication refill percentage.

*p < 0.0001 for group comparison parameter estimate in the regression.

Abbreviations: CCB, calcium channel blocker; PDC, proportion of days covered.

Figure 3 (A) Estimated unadjusted Kaplan-Meier curves for time to therapy discontinuation, and (B) adjusted hazard ratio of discontinuing therapies. Proportional hazard model analysis adjusting for covariates including age, gender, business type, formulary type, baseline antihypertensive therapy, cardiovascular disease medications, antidiabetic medications, antidepressants, number of drugs, co-payments, and maintenance medication refill percentage.

*p < 0.0001 for group comparison parameter estimate in the regression.

Figure 4 Adjusted probability of achieving adherence (PDC ≥ 80%), over 1-year follow-up. Logistic regression model analysis adjusting for covariates including age, gender, business type, formulary type, baseline antihypertensive therapy, cardiovascular disease medications, antidiabetic medications, antidepressants, number of drugs, co-payments, and maintenance medication refill percentage.

*p < 0.0001 for group comparison parameter estimate in the regression.

Abbreviations: CCB, calcium channel blocker; PDC, proportion of days covered.

First DataBank IncNDDF File2006San Bruno, CAThe Hearst Corporation

 Google Scholar